However, antibodies against Caspr1 have only been reported in less than ten CIDP patients, and larger studies are needed to ascertain the specific features associated with these antibodies [7, 11, 12]. This evidence concerns the gene CNTNAP1 and chronic inflammatory demyelinating polyradiculoneuropathy.